百癣夏塔热片联合夫西地酸乳膏治疗寻常痤疮的临床研究
|
摘要
目的探讨百癣夏塔热片联合夫西地酸乳膏治疗寻常痤疮的临床疗效。方法选取2017年6月—2018年6月在监利县人民医院治疗的寻常痤疮患者98例,根据用药的不同分为对照组(49例)和治疗组(49例)。对照组患者取适量夫西地酸乳膏涂于患处,3次/d;治疗组在对照组基础上口服百癣夏塔热片,1.55 g/次,3次/d。两组患者均治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者红斑、色素沉着、Acne-QOL和SF-36评分及血清白细胞介素-8(IL-8)、可溶性白细胞介素-2受体(sIL-2R)、肿瘤坏死因子-α(TNF-α)、IL-10和γ干扰素(IFN-γ)水平。结果治疗后,对照组临床有效率为81.63%,显著低于治疗组的97.96%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者红斑、色素沉着评分显著降低(P<0.05),Acne-QOL和SF-36评分显著升高(P<0.05),且治疗组红斑、色素沉着、Acne-QOL和SF-36评分明显优于对照组(P<0.05)。治疗后,两组患者血清IL-8、s IL-2R和TNF-α水平均显著降低(P<0.05),IL-10和IFN-γ水平显著升高(P<0.05),且治疗组上述炎症因子水平明显好于对照组(P<0.05)。结论百癣夏塔热片联合夫西地酸乳膏治疗寻常痤疮可有效改善患者临床症状,促进皮损修复,降低机体炎症反应,提高患者生活质量。
Objective To investigate the clinical efficacy of Baixian Xiatare Tablets combined with Fusidic Acid Cream in treatment of acne vulgaris. Methods Patients(98 cases) with acne vulgaris in Jianli County People's Hospital from June 2017 to June 2018 were divided into control(49 cases) and treatment(49 cases) groups according to different treatments. Patients in the control group were administered with Fusidic Acid Cream on the lesion, three times daily. Patients in the treatment group were po administered with Baixian Xiatare Tablets on the basis of the control group, 1.55 g/time, three times daily. Patients in two groups were treated for 4 weeks.After treatment, the clinical efficacy was evaluated, and the erythema, pigmentation, Acne-QOL and SF-36 scores, and serum IL-8,sIL-2 R, TNF-α, IL-10 and IFN-γ levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.63%, which was significantly lower than 97.96% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the erythema and pigmentation scores in two groups were significantly decreased(P < 0.05), but Acne-QOL and SF-36 were significantly increased(P < 0.05), and these scores in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the serum IL-8, sIL-2 R, and TNF-α levels in two groups were significantly decreased(P < 0.05), but IL-10 and IFN-γ levels were significantly increased(P < 0.05), and these inflammatory factors levels in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Baixian Xiatare Tablets combined with Fusidic Acid Cream in treatment of acne vulgaris can effectively improve the clinical symptoms, promote the repair of skin lesions, reduce inflammation, improve the quality of life.
Objective To investigate the clinical efficacy of Baixian Xiatare Tablets combined with Fusidic Acid Cream in treatment of acne vulgaris. Methods Patients(98 cases) with acne vulgaris in Jianli County People's Hospital from June 2017 to June 2018 were divided into control(49 cases) and treatment(49 cases) groups according to different treatments. Patients in the control group were administered with Fusidic Acid Cream on the lesion, three times daily. Patients in the treatment group were po administered with Baixian Xiatare Tablets on the basis of the control group, 1.55 g/time, three times daily. Patients in two groups were treated for 4 weeks.After treatment, the clinical efficacy was evaluated, and the erythema, pigmentation, Acne-QOL and SF-36 scores, and serum IL-8,sIL-2 R, TNF-α, IL-10 and IFN-γ levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.63%, which was significantly lower than 97.96% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the erythema and pigmentation scores in two groups were significantly decreased(P < 0.05), but Acne-QOL and SF-36 were significantly increased(P < 0.05), and these scores in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the serum IL-8, sIL-2 R, and TNF-α levels in two groups were significantly decreased(P < 0.05), but IL-10 and IFN-γ levels were significantly increased(P < 0.05), and these inflammatory factors levels in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Baixian Xiatare Tablets combined with Fusidic Acid Cream in treatment of acne vulgaris can effectively improve the clinical symptoms, promote the repair of skin lesions, reduce inflammation, improve the quality of life.
引文
[1]伯勋.现代实用皮肤病学[M].西安:世界图书出版西安公司,2007:681-682.
[2]黄晔,竺璐,吴晓金.夫西地酸乳膏联合维A酸乳膏治疗寻常痤疮疗效观察[J].临床皮肤科杂志,2018,47(1):50-51.
[3]吴威犟,朱宏明.百癣夏塔热片治疗寻常痤疮54例疗效观察[J].浙江中医药大学学报,2012,36(6):660-661.
[4]高天文,刘玮.皮肤美容科学[M].北京:人民卫生出版社,2012:167-168.
[5]阿不都外力·阿不都克里木,斯拉甫·艾白,王平山,等.维药新药治疗寻常痤疮的临床研究指导原则(草案)[J].中国中医药信息杂志,2017,24(2):1-4.
[6]Goodman G J,Baron J A.Postacne scarring:a quantitative global scarring grading system[J].Dermatol Surg,2006,32(12):1458-1466.
[7]杜丹,李晓雪,潘瑜,等.简化版《痤疮特异性生活质量调查问卷》在四川地区汉族人群中的信度和效度分析[J].四川大学学报:医学版,2017,48(2):272-275.
[8]张颂楠,王昊,支媛婷,等.国内中重度痤疮药物治疗的临床研究质量评价[J].中国医疗管理科学,2016,6(2):70-72.
[9]林新瑜,罗旭松,董巍,等.痤疮患者血清白介素-1α、白介素-6、白介素-8和α-肿瘤坏死因子水平的检测分析[J].临床皮肤科杂志,2003,32(6):335-336.
[10]张乳霞,张福仁,张茂修.女性痤疮患者血清IL-1α、sIL-2R和TNF-α水平的检测[J].医学检验与临床,2007,18(1):31-32.
[11]易娟娟,刘俊,唐妍,等.痤疮患者血清IL-10水平的检测及其意义[J].皮肤性病诊疗学杂志,2015,22(4):296-298.
[12]冯凯.奥硝唑联合阿奇霉素治疗寻常型痤疮对患者血清炎症因子水平的影响[J].海峡药学,2018,30(11):120-122.
[2]黄晔,竺璐,吴晓金.夫西地酸乳膏联合维A酸乳膏治疗寻常痤疮疗效观察[J].临床皮肤科杂志,2018,47(1):50-51.
[3]吴威犟,朱宏明.百癣夏塔热片治疗寻常痤疮54例疗效观察[J].浙江中医药大学学报,2012,36(6):660-661.
[4]高天文,刘玮.皮肤美容科学[M].北京:人民卫生出版社,2012:167-168.
[5]阿不都外力·阿不都克里木,斯拉甫·艾白,王平山,等.维药新药治疗寻常痤疮的临床研究指导原则(草案)[J].中国中医药信息杂志,2017,24(2):1-4.
[6]Goodman G J,Baron J A.Postacne scarring:a quantitative global scarring grading system[J].Dermatol Surg,2006,32(12):1458-1466.
[7]杜丹,李晓雪,潘瑜,等.简化版《痤疮特异性生活质量调查问卷》在四川地区汉族人群中的信度和效度分析[J].四川大学学报:医学版,2017,48(2):272-275.
[8]张颂楠,王昊,支媛婷,等.国内中重度痤疮药物治疗的临床研究质量评价[J].中国医疗管理科学,2016,6(2):70-72.
[9]林新瑜,罗旭松,董巍,等.痤疮患者血清白介素-1α、白介素-6、白介素-8和α-肿瘤坏死因子水平的检测分析[J].临床皮肤科杂志,2003,32(6):335-336.
[10]张乳霞,张福仁,张茂修.女性痤疮患者血清IL-1α、sIL-2R和TNF-α水平的检测[J].医学检验与临床,2007,18(1):31-32.
[11]易娟娟,刘俊,唐妍,等.痤疮患者血清IL-10水平的检测及其意义[J].皮肤性病诊疗学杂志,2015,22(4):296-298.
[12]冯凯.奥硝唑联合阿奇霉素治疗寻常型痤疮对患者血清炎症因子水平的影响[J].海峡药学,2018,30(11):120-122.